JP2016519763A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016519763A5 JP2016519763A5 JP2016503081A JP2016503081A JP2016519763A5 JP 2016519763 A5 JP2016519763 A5 JP 2016519763A5 JP 2016503081 A JP2016503081 A JP 2016503081A JP 2016503081 A JP2016503081 A JP 2016503081A JP 2016519763 A5 JP2016519763 A5 JP 2016519763A5
- Authority
- JP
- Japan
- Prior art keywords
- lung disease
- fibrotic lung
- expression level
- subject
- biological sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000019693 Lung disease Diseases 0.000 claims 50
- 230000003176 fibrotic effect Effects 0.000 claims 49
- 108090000623 proteins and genes Proteins 0.000 claims 41
- 102000004169 proteins and genes Human genes 0.000 claims 39
- 239000003550 marker Substances 0.000 claims 24
- 239000012472 biological sample Substances 0.000 claims 14
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 230000000750 progressive effect Effects 0.000 claims 8
- 210000004369 blood Anatomy 0.000 claims 6
- 239000008280 blood Substances 0.000 claims 6
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 4
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 4
- 239000000523 sample Substances 0.000 claims 4
- 239000000556 agonist Substances 0.000 claims 3
- 239000005557 antagonist Substances 0.000 claims 3
- 230000003247 decreasing effect Effects 0.000 claims 3
- 108091023037 Aptamer Proteins 0.000 claims 2
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 2
- 210000001124 body fluid Anatomy 0.000 claims 2
- 239000010839 body fluid Substances 0.000 claims 2
- 230000009266 disease activity Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 210000002381 plasma Anatomy 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 210000003296 saliva Anatomy 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 150000003384 small molecules Chemical class 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 210000002700 urine Anatomy 0.000 claims 2
- 102000007469 Actins Human genes 0.000 claims 1
- 108010085238 Actins Proteins 0.000 claims 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 claims 1
- 239000003172 expectorant agent Substances 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 claims 1
- 229940066491 mucolytics Drugs 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361801476P | 2013-03-15 | 2013-03-15 | |
| US201361801290P | 2013-03-15 | 2013-03-15 | |
| US61/801,476 | 2013-03-15 | ||
| US61/801,290 | 2013-03-15 | ||
| US201361874947P | 2013-09-06 | 2013-09-06 | |
| US61/874,947 | 2013-09-06 | ||
| PCT/US2014/029392 WO2014144821A1 (en) | 2013-03-15 | 2014-03-14 | Proteomic ipf markers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016519763A JP2016519763A (ja) | 2016-07-07 |
| JP2016519763A5 true JP2016519763A5 (enExample) | 2017-04-13 |
Family
ID=51537804
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016503081A Pending JP2016519763A (ja) | 2013-03-15 | 2014-03-14 | プロテオームｉｐｆマーカー |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9726677B2 (enExample) |
| EP (1) | EP2972392A4 (enExample) |
| JP (1) | JP2016519763A (enExample) |
| KR (1) | KR20150130408A (enExample) |
| CN (1) | CN105122068A (enExample) |
| BR (1) | BR112015023699A2 (enExample) |
| CA (1) | CA2901384A1 (enExample) |
| HK (1) | HK1219533A1 (enExample) |
| MX (1) | MX2015012778A (enExample) |
| RU (1) | RU2015144149A (enExample) |
| WO (1) | WO2014144821A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10236078B2 (en) | 2008-11-17 | 2019-03-19 | Veracyte, Inc. | Methods for processing or analyzing a sample of thyroid tissue |
| EP3360978A3 (en) | 2009-05-07 | 2018-09-26 | Veracyte, Inc. | Methods for diagnosis of thyroid conditions |
| JP2016519763A (ja) | 2013-03-15 | 2016-07-07 | インターミューン， インコーポレイテッド | プロテオームｉｐｆマーカー |
| US11976329B2 (en) | 2013-03-15 | 2024-05-07 | Veracyte, Inc. | Methods and systems for detecting usual interstitial pneumonia |
| US12297505B2 (en) | 2014-07-14 | 2025-05-13 | Veracyte, Inc. | Algorithms for disease diagnostics |
| US20170335396A1 (en) | 2014-11-05 | 2017-11-23 | Veracyte, Inc. | Systems and methods of diagnosing idiopathic pulmonary fibrosis on transbronchial biopsies using machine learning and high dimensional transcriptional data |
| ES2957464T3 (es) * | 2017-04-14 | 2024-01-19 | Univ Arizona | Composiciones y métodos para tratar fibrosis pulmonar |
| WO2018191747A1 (en) | 2017-04-14 | 2018-10-18 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions and methods for treating pulmonary arterial hypertension |
| CN107677835B (zh) * | 2017-09-26 | 2019-08-09 | 上海市肺科医院 | 一种ae-ipf的蛋白标记物及其应用 |
| BR112021002728A2 (pt) * | 2018-08-17 | 2021-08-10 | F. Hoffmann-La Roche Ag | métodos de avaliação da fibrilação atrial, de auxílio à avaliação da fibrilação atrial, de diagnóstico de insuficiência cardíaca e de predição do risco de hospitalização, método implementado por computador para a avaliação da fibrilação atrial, kit e usos in vitro |
| WO2020090683A1 (ja) * | 2018-10-29 | 2020-05-07 | 国立大学法人東京医科歯科大学 | 間質性肺炎患者の呼吸機能の低下リスクに関する情報を取得する方法及びその利用 |
| JP7300642B2 (ja) * | 2019-06-14 | 2023-06-30 | 国立大学法人浜松医科大学 | 特発性肺線維症の予後予測方法 |
| CN110333358A (zh) * | 2019-06-24 | 2019-10-15 | 浙江大学 | 一种急性肺损伤小鼠肺脏全免疫细胞特征图谱的建立方法 |
| JP7614477B2 (ja) * | 2019-08-02 | 2025-01-16 | 国立医薬品食品衛生研究所長 | 間質性肺炎のタンパク質診断バイオマーカー |
| US20230129866A1 (en) * | 2020-03-13 | 2023-04-27 | Puretech Lyt 100, Inc. | Methods of treating respiratory disease with deupirfenidone |
| US20230146286A1 (en) * | 2020-04-17 | 2023-05-11 | Japan As Represented By Director General Of National Institute Of Health Sciences | Protein diagnostic biomarker for severe drug eruption |
| CN113607955A (zh) * | 2020-09-16 | 2021-11-05 | 广州中医药大学顺德医院(佛山市顺德区中医院) | 新型冠状病毒肺炎分期与疗效评估细胞因子标志物及其应用 |
| CN113533750A (zh) * | 2020-10-22 | 2021-10-22 | 广州中医药大学顺德医院(佛山市顺德区中医院) | 一种区分新型冠状病毒肺炎患者与健康者的系统 |
| US20250122293A1 (en) * | 2021-09-07 | 2025-04-17 | Fnct Biotech, Inc. | Csf3r as biomarker and therapeutic target for pulmonary fibrosis |
| WO2023081299A1 (en) * | 2021-11-05 | 2023-05-11 | Spiritus Therapeutics, Inc. | A purified enriched population exosomes derived from individuals with a chronic progressive lung disease for noninvasive detection, staging, and medical monitoring of disease progression |
| CN114563562A (zh) * | 2022-03-01 | 2022-05-31 | 复旦大学附属中山医院 | Prdx6联合铁离子检测在ards进程监测中的应用 |
| KR102907646B1 (ko) * | 2022-08-19 | 2026-01-05 | 울산대학교 산학협력단 | 특발성 폐섬유증 환자의 진단 및 경과예측용 호기 바이오마커 |
| WO2024068386A1 (en) * | 2022-09-28 | 2024-04-04 | Boehringer Ingelheim International Gmbh | Use of biomarkers in the treatment of fibrotic conditions with a pde4b-inhibitor |
| CN117025745B (zh) * | 2022-11-18 | 2024-02-23 | 中国医学科学院北京协和医院 | 分子标志物在诊断干燥综合征中的应用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US5235033A (en) | 1985-03-15 | 1993-08-10 | Anti-Gene Development Group | Alpha-morpholino ribonucleoside derivatives and polymers thereof |
| US5637459A (en) | 1990-06-11 | 1997-06-10 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: chimeric selex |
| US5496938A (en) | 1990-06-11 | 1996-03-05 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligands to HIV-RT and HIV-1 rev |
| US5582981A (en) | 1991-08-14 | 1996-12-10 | Gilead Sciences, Inc. | Method for identifying an oligonucleotide aptamer specific for a target |
| US6019988A (en) * | 1996-11-18 | 2000-02-01 | Bristol-Myers Squibb Company | Methods and compositions for enhancing skin permeation of drugs using permeation enhancers, when drugs and/or permeation enhancers are unstable in combination during long-term storage |
| DE60237969D1 (de) * | 2001-04-24 | 2010-11-25 | Bayer Corp | Menschliche antikörper gegen timp-1 |
| AUPR638101A0 (en) * | 2001-07-13 | 2001-08-09 | Bioa Pty Limited | Composition and method for treatment of disease |
| JP2003238592A (ja) * | 2001-12-13 | 2003-08-27 | Japan Tobacco Inc | 組織及び血管の再生のための医薬及びその方法 |
| AR040603A1 (es) | 2002-07-19 | 2005-04-13 | Abbott Lab S A | El uso de un anticuerpo anti-tnfalfa neutralizador de alta afinidad en la fabricacion de un medicamento y conjunto de elementos |
| US7888485B2 (en) * | 2003-03-26 | 2011-02-15 | Georgetown University | Anti-pleiotrophin antibodies and methods of use thereof |
| US20060211752A1 (en) * | 2004-03-16 | 2006-09-21 | Kohn Leonard D | Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression |
| EP1626279B1 (en) * | 2004-08-12 | 2008-04-16 | Roche Diagnostics GmbH | Method for diagnosing liver fibrosis |
| CA2596986A1 (en) * | 2005-02-14 | 2006-08-24 | Wyeth | Use of il-17f in diagnosis and therapy of airway inflammation |
| EP1757940A1 (en) * | 2005-08-26 | 2007-02-28 | Cézanne S.A.S. | In vitro method for diagnosing and monitoring renal cell carcinoma (RCC) using MMP-7 as humoral biomarker for RCC |
| US20110129845A1 (en) * | 2007-01-29 | 2011-06-02 | Crc For Asthma And Airways Ltd. | Method of diagnosis |
| JP2010536844A (ja) * | 2007-08-24 | 2010-12-02 | オンコセラピー・サイエンス株式会社 | 癌の治療標的及び診断マーカーとしてのｄｋｋ１癌遺伝子 |
| WO2010028274A1 (en) | 2008-09-05 | 2010-03-11 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Marker panels for idiopathic pulmonary fibrosis diagnosis and evaluation |
| US8568996B2 (en) * | 2008-10-21 | 2013-10-29 | University of Pittsburgh—of the Commonwealth System of Higher Education | MMP activation peptide detection in biological samples |
| US20110280865A1 (en) * | 2009-01-16 | 2011-11-17 | The Ohio State University | Ets-2 Biomarkers for Fibrotic Diseases and Uses Thereof |
| US20100227335A1 (en) * | 2009-03-05 | 2010-09-09 | Becton, Dickinson And Company | Matrix metalloproteinase-7 (mmp-7) monoclonal antibodies and methods for their use in the detection of ovarian cancer |
| CN102448984A (zh) * | 2009-03-27 | 2012-05-09 | 酶遗传学股份有限公司 | 使用包含抗体-受体组合的多特异性结合蛋白的组合物和方法 |
| CN102711820A (zh) * | 2009-08-21 | 2012-10-03 | 吉联亚生物科技有限公司 | 治疗肺纤维化疾病的方法和组合物 |
| EP2496944A2 (en) * | 2009-11-05 | 2012-09-12 | Novartis AG | Biomarkers predictive of progression of fibrosis |
| WO2011091270A2 (en) * | 2010-01-21 | 2011-07-28 | The Regents Of The University Of Michigan | Biomarkers for lung disease monitoring |
| US20130078252A1 (en) * | 2011-09-19 | 2013-03-28 | Genentech, Inc. | Combination treatments comprising c-met antagonists and b-raf antagonists |
| JP2016519763A (ja) | 2013-03-15 | 2016-07-07 | インターミューン， インコーポレイテッド | プロテオームｉｐｆマーカー |
-
2014
- 2014-03-14 JP JP2016503081A patent/JP2016519763A/ja active Pending
- 2014-03-14 EP EP14762377.1A patent/EP2972392A4/en not_active Withdrawn
- 2014-03-14 MX MX2015012778A patent/MX2015012778A/es unknown
- 2014-03-14 CA CA2901384A patent/CA2901384A1/en not_active Abandoned
- 2014-03-14 KR KR1020157027988A patent/KR20150130408A/ko not_active Withdrawn
- 2014-03-14 BR BR112015023699A patent/BR112015023699A2/pt not_active IP Right Cessation
- 2014-03-14 WO PCT/US2014/029392 patent/WO2014144821A1/en not_active Ceased
- 2014-03-14 HK HK16107519.9A patent/HK1219533A1/zh unknown
- 2014-03-14 RU RU2015144149A patent/RU2015144149A/ru unknown
- 2014-03-14 US US14/213,970 patent/US9726677B2/en active Active - Reinstated
- 2014-03-14 CN CN201480021359.5A patent/CN105122068A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016519763A5 (enExample) | ||
| RU2015144149A (ru) | Протеомные маркеры илф | |
| Adams et al. | Molecular effects of exercise training in patients with cardiovascular disease: focus on skeletal muscle, endothelium, and myocardium | |
| Wigén et al. | Converging pathways in pulmonary fibrosis and Covid-19-the fibrotic link to disease severity | |
| JP6778112B2 (ja) | 抗インフルエンザウイルス剤、及び抗インフルエンザウイルス剤のスクリーニング方法 | |
| Arron et al. | Noninvasive biomarkers that predict treatment benefit from biologic therapies in asthma | |
| Roy et al. | De novo design of highly selective miniprotein inhibitors of integrins αvβ6 and αvβ8 | |
| Casu et al. | Can changes in renal function predict variations in β-lactam concentrations in septic patients? | |
| Gong et al. | Interplay of VEGFa and MMP2 regulates invasion of glioblastoma | |
| US20210260113A1 (en) | Devices, methods, compositions and systems for the treatment of aging and age-related disorders | |
| JP6755241B2 (ja) | 新規分子バイオマーカーを使用して慢性閉塞性肺疾患（ｃｏｐｄ）を診断する方法 | |
| JP6755240B2 (ja) | 新規分子バイオマーカーを使用して慢性閉塞性肺疾患（ｃｏｐｄ）を診断する方法 | |
| JP6755242B2 (ja) | 新規分子バイオマーカーを使用して慢性閉塞性肺疾患（ｃｏｐｄ）を診断する方法 | |
| KR20230169484A (ko) | 미오스타틴 억제제의 용도 및 조합 요법 | |
| Zeballos C et al. | Mitigating a TDP-43 proteinopathy by targeting ataxin-2 using RNA-targeting CRISPR effector proteins | |
| JP2015521050A5 (enExample) | ||
| JP2010524432A5 (enExample) | ||
| JP2022008641A5 (enExample) | ||
| JP2016522163A5 (enExample) | ||
| JP2015505245A5 (enExample) | ||
| JP2016528914A5 (enExample) | ||
| D’Haese et al. | The impact of MFG-E8 in chronic pancreatitis: potential for future immunotherapy? | |
| RU2013104137A (ru) | Изоформы bard1 при раке легкого и колоректальном раке и их применение | |
| Mederacke et al. | Renal function during treatment with adefovir plus peginterferon alfa‐2a vs either drug alone in hepatitis B/D co‐infection | |
| US11559517B2 (en) | Promotion of epithelial repair |